131 related articles for article (PubMed ID: 26356810)
21. Strategies to optimize siRNA delivery to hepatocellular carcinoma cells.
Scarabel L; Perrone F; Garziera M; Farra R; Grassi M; Musiani F; Russo Spena C; Salis B; De Stefano L; Toffoli G; Rizzolio F; Tonon F; Abrami M; Chiarappa G; Pozzato G; Forte G; Grassi G; Dapas B
Expert Opin Drug Deliv; 2017 Jun; 14(6):797-810. PubMed ID: 28266887
[TBL] [Abstract][Full Text] [Related]
22. Biodistribution and improved anticancer effect of NIK-siRNA in combination with 5-FU for hepatocellular carcinoma.
Kang SS; Cho HA; Kim JS
Arch Pharm Res; 2011 Jan; 34(1):79-86. PubMed ID: 21468918
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis B virus core protein enhances human telomerase reverse transcriptase expression and hepatocellular carcinoma cell proliferation in a c-Ets2-dependent manner.
Gai X; Zhao P; Pan Y; Shan H; Yue X; Du J; Zhang Z; Liu P; Ma H; Guo M; Yang X; Sun W; Gao L; Ma C; Liang X
Int J Biochem Cell Biol; 2013 Jul; 45(7):1174-85. PubMed ID: 23542016
[TBL] [Abstract][Full Text] [Related]
24. Anti-tumor activity of KNTC2 siRNA in orthotopic tumor model mice of hepatocellular carcinoma.
Makita Y; Murata S; Katou Y; Kikuchi K; Uejima H; Teratani M; Hoashi Y; Kenjo E; Matsumoto S; Nogami M; Otake K; Kawamata Y
Biochem Biophys Res Commun; 2017 Nov; 493(1):800-806. PubMed ID: 28843857
[TBL] [Abstract][Full Text] [Related]
25. RNA interference against granulin-epithelin precursor prevents hepatocellular carcinoma growth: its application as a therapeutic agent.
Park MY; Park YS; Nam JH
Int J Oncol; 2011 Oct; 39(4):853-61. PubMed ID: 21701774
[TBL] [Abstract][Full Text] [Related]
26. HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma.
Momosaki S; Nakashima Y; Kojiro M; Tabor E
J Viral Hepat; 2005 May; 12(3):325-9. PubMed ID: 15850475
[TBL] [Abstract][Full Text] [Related]
27. Pokemon silencing leads to Bim-mediated anoikis of human hepatoma cell QGY7703.
Liu K; Liu F; Zhang N; Liu S; Jiang Y
Int J Mol Sci; 2012; 13(5):5818-5831. PubMed ID: 22754333
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of connective tissue growth factor overexpression decreases growth of hepatocellular carcinoma cells in vitro and in vivo.
Jia XQ; Cheng HQ; Li H; Zhu Y; Li YH; Feng ZQ; Zhang JP
Chin Med J (Engl); 2011 Nov; 124(22):3794-9. PubMed ID: 22340243
[TBL] [Abstract][Full Text] [Related]
29. Intracellular single-chain antibody against hepatitis B virus core protein inhibits the replication of hepatitis B virus in cultured cells.
Yamamoto M; Hayashi N; Takehara T; Ueda K; Mita E; Tatsumi T; Sasaki Y; Kasahara A; Hori M
Hepatology; 1999 Jul; 30(1):300-7. PubMed ID: 10385671
[TBL] [Abstract][Full Text] [Related]
30. The effect of Pokemon on bladder cancer epithelial-mesenchymal transition.
Guo C; Zhu K; Sun W; Yang B; Gu W; Luo J; Peng B; Zheng J
Biochem Biophys Res Commun; 2014 Jan; 443(4):1226-31. PubMed ID: 24393848
[TBL] [Abstract][Full Text] [Related]
31. Antibody to hepatitis B core antigen is associated with the development of hepatocellular carcinoma in hepatitis C virus-infected persons: a 12-year prospective study.
Tanaka K; Nagao Y; Ide T; Kumashiro R; Sata M
Int J Mol Med; 2006 May; 17(5):827-32. PubMed ID: 16596267
[TBL] [Abstract][Full Text] [Related]
32. HBV DNA integration and HBV-transcript expression in non-B, non-C hepatocellular carcinoma in Japan.
Tamori A; Nishiguchi S; Kubo S; Narimatsu T; Habu D; Takeda T; Hirohashi K; Shiomi S
J Med Virol; 2003 Dec; 71(4):492-8. PubMed ID: 14556260
[TBL] [Abstract][Full Text] [Related]
33. Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes.
Yin T; Wang P; Li J; Wang Y; Zheng B; Zheng R; Cheng D; Shuai X
Biomaterials; 2014 Jul; 35(22):5932-43. PubMed ID: 24746965
[TBL] [Abstract][Full Text] [Related]
34. Efficient inhibition of hepatitis B virus replication by small interfering RNAs targeted to the viral X gene in mice.
Shin D; Kim SI; Kim M; Park M
Virus Res; 2006 Aug; 119(2):146-53. PubMed ID: 16443303
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of hepatitis-B-virus core promoter by p53: implications for carcinogenesis in hepatocytes.
Uchida T; Takahashi K; Tatsuno K; Dhingra U; Eliason JF
Int J Cancer; 1996 Sep; 67(6):892-7. PubMed ID: 8824564
[TBL] [Abstract][Full Text] [Related]
36. Notch1 is a potential therapeutic target for the treatment of human hepatitis B virus X protein-associated hepatocellular carcinoma.
Sun Q; Wang R; Wang Y; Luo J; Wang P; Cheng B
Oncol Rep; 2014 Feb; 31(2):933-9. PubMed ID: 24336972
[TBL] [Abstract][Full Text] [Related]
37. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.
Marotta F; Vangieri B; Cecere A; Gattoni A
Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567
[TBL] [Abstract][Full Text] [Related]
38. Anti-hepatitis B core positivity as a risk factor for hepatocellular carcinoma in alcoholic cirrhosis: a case-control study.
Kwon OS; Jung YK; Bae KS; Kim JH; Kim SG; Kim YS; Lee JI; Lee JW; Kim YS
Alcohol; 2012 Sep; 46(6):537-41. PubMed ID: 22572059
[TBL] [Abstract][Full Text] [Related]
39. Transcriptional repression of the human p53 gene by hepatitis B viral core protein (HBc) in human liver cells.
Kwon JA; Rho HM
Biol Chem; 2003 Feb; 384(2):203-12. PubMed ID: 12675512
[TBL] [Abstract][Full Text] [Related]
40. Possible contribution of prior hepatitis B virus infection to the development of hepatocellular carcinoma.
Tanaka H; Iwasaki Y; Nouso K; Kobayashi Y; Nakamura S; Matsumoto E; Toshikuni N; Kaneyoshi T; Ohsawa T; Takaguchi K; Fujio K; Senoh T; Ohnishi T; Sakaguchi K; Shiratori Y
J Gastroenterol Hepatol; 2005 Jun; 20(6):850-6. PubMed ID: 15946131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
